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Summary box
► In 1988, the World Health Assembly resolved to eradicate poliomyelitis by the year 2000, resulting in an unprecedented effort to combat one of the major sources of permanent disability. Impressive progress has been achieved, however eradication remains elusive. ► Four of six WHO Regions have been certified as free of the three wild poliovirus serotypes-of the two remaining WHO Regions, the African Region is close to certification, but Afghanistan and Pakistan (in the Eastern Mediterranean Region) remain endemic for wild poliovirus type 1. ► The major challenges relate to access, conflict and the quality of campaign activities, and increasingly, vaccine hesitancy-in this context, the move to a control programme, rather than continuing efforts to achieve eradication, seems like a logical question to raise. ► But this is an unrealistic expectation; controlling the circulation of the polio virus is impossible, because there are many settings with low routine immunisation coverage-if we abandon eradication efforts, we would have to brace for high numbers of outbreaks and children with permanent disabilities. ► The global polio eradication objective is feasible, as has been demonstrated repeatedly, over very large geographic areas such as the entire Western hemisphere and the Indian subcontinent, and can be secured as the Region of the Americas has demonstrated since 1991. ► Ultimately, the world must decide whether the global good of polio eradication is worth achieving-and to move forward, ownership in the two remaining countries and continuous improvement of eradication efforts is of paramount importance to which the Global Polio Eradication Initiative remains committed.
In 1988, the World Health Assembly, the governing body of the WHO, resolved to eradicate poliomyelitis by the year 2000. 6 have been certified by Regional Certification Commissions as free of the three wild poliovirus serotypes. This certification process has been robust, few importations of wild poliovirus into the European and Western Pacific Regions were documented and the ensuing outbreaks were rapidly and fully stopped. 7 8 Two WHO Regions (the African Region and the Eastern Mediterranean Region (EMR))
have not yet achieved this milestone. The African Region is close to certification with the last isolation of wild poliovirus occurring in September 2016. Two countries in EMR (Afghanistan and Pakistan) remain endemic for wild poliovirus type 1. The 'last inch' is indeed very difficult to achieve in the last two remaining countries. A number of new and old challenges stop the programme tantalising short of eradication. The major ones are access to the population because of conflict and the quality of campaign activities. The programme is increasingly affected by vaccine hesitancy and security. In this context, the move to a control programme, rather than continuing efforts to achieve eradication, seems like a logical question to raise.
The progress in the WHO polio-free Regions encouraged the preparation and implementation of a new endgame strategy 9 that called for the withdrawal of Sabin type 2 from the trivalent oral poliovirus vaccine (tOPV) in 2016 (ie, 'the switch'), as a first step to an OPV-free world. Currently, efforts are ongoing to stop outbreaks in sub-Saharan and the Horn of Africa of circulating vaccine-derived poliovirus type 2 (cVDPV2), a virus that originates from the vaccine and was seeded from tOPV before the switch or monovalent type 2 OPV (mOPV2) use after the switch.
The Global Polio Eradication Initiative (GPEI) anticipated, based on modelling, 10 11 the occurrence of cVDPV2 outbreaks in the period following the switch. A global stockpile of >500 million doses of mOPV2 was contracted with two manufacturers. What the programme was less prepared for was that the outbreak control activities with mOPV2 could rapidly lead to the new emergence of cVDPV2, mainly due to poor campaign quality, and the spread of the cVDPV2 outbreak virus into adjacent geographies and across borders. For the control efforts to be successful, a high proportion of the targeted children needs to receive the vaccine.
Over the years, there have been repeated calls for converting the eradication initiative into a control programme. 12 13 Writing in BMJ Global Health, Razum et al 14 suggest that we abandon the eradication target and replace it with 'sustained control'. For us, this is an unrealistic objective which was debated in previous communications. 15 16 Although 'sustained control' is not defined by the authors, we assume it to mean that we could maintain the accomplishments (few paralytic cases due to poliovirus) and divert the polio eradication funding to universal health coverage. In an epidemic-prone disease, such as poliomyelitis, we have experienced over and over during the past decades that control at low endemicity is impossible, primarily because of the large number of countries or areas or population groups with low routine immunisation coverage which leaves way to outbreaks. In an almost decade-old study in The Lancet, 12 Thompson and Tebbens estimated that in a low very control scenario the incidence of paralytic poliomyelitis would reach approximately 200 000 cases globally per year. Thus, if we abandon the eradication efforts, we would have to brace for high numbers of children with permanent disabilities.
It is hard to put a value on a child who walks today because poliovirus did not cause permanent paralysis. In a simple back of the envelope calculation, we use the number paralysis averted by the GPEI, approximately 18 million between 1988 and 2018, as numerator, and the external contributions during 1985-2018 used as denominator, approximately US$14.5 billion. 17 This puts a value of $800 per paralysis averted. Although this is an underestimate since it does not capture the national contributions, it reflects the generous external contributions of the donor community. In addition, if we assume that the case fatality ratio among paralytic poliomyelitis cases is between 5% and 10%, between 900 000 and 1 800 000 infants are alive today because of the eradication efforts. Would these accomplishments be worth preserving for the future?
The GPEI is spearheaded by six partners (Rotary International, Gavi (the Vaccine Alliance), the US Centers for Disease Control and Prevention, the Bill and Melinda Gates Foundation, UNICEF and WHO), supported by multilateral and bilateral health and development aid organisations, private industry and the governments of the affected countries. Polio eradication remains one of the largest public-private sector collaborations to achieve a public health goal. Despite substantial challenges along the eradication pathway, these partners remain committed to see eradication to the ultimate conclusion.
The global programme has mastered many challenges, including a ban on polio vaccination in Northern Nigeria in 2004, 18 the low immunogenicity of polio vaccines in Northern India, 19 the inaccessibility of most of Borno State, Nigeria, 20 and the targeting of polio workers for assassination in Pakistan, 21 to mention but a few. Much has been overcome, but much more needs to be done.
Thus, Razum et al 14 are correct when they write 'There is one strategy, however, that the world should not be content with: namely more of the same.' More of the same has brought the polio eradication effort very close to the finish line, but indeed the last two countries must assume much greater responsibility for the programme, coordinate their efforts and make eradication their national priority.
The cVDPV2 outbreaks in sub-Saharan Africa require both quality improvements in field activities and a technological solution. The current mOPV2 relying on Sabin strains is inherently genetically instable and its use will always be associated with the risk of new emergences of cVDPV2. This problem was recognised by the GPEI almost a decade ago, and an ambitious research agenda resulted in the first in human use of a genetically more stable new type 2 OPV (nOPV2). 22 Subsequent clinical trials are under way, and if the vaccine performs as expected, in 12-18 months the large-scale use of nOPV2 will demonstrate whether we can retire the Sabin type 2 strains to history.
Eradication is difficult, and the GPEI is the first to acknowledge the remaining challenges. New commitments, efforts and strategies are indeed needed. The global community has also realised that the polio eradication programme cannot be the panacea for solving ethnic strife, civil war or inaccessibility for delivering the polio vaccines and conduct surveillance. The problems require country leadership and ownership.
We agree with Razum et al 14 that while there have been many achievements to date, many problems remain that continue to delay the initiative reaching the eradication target. What we do not agree with is the proposed solution. The GPEI made a promise to ensure no child will ever be paralysed by the polioviruses. The global polio eradication objective is feasible, as has been demonstrated repeatedly, over very large geographic areas such as the entire Western hemisphere and the Indian subcontinent, and can be secured as the Region of the Americas BMJ Global Health has demonstrated since 1991 (almost 28 years without paralysis caused by wild polioviruses). 3 To move forward, country ownership in the two remaining countries is of paramount importance. We also need to critically review the eradication strategies and be bold where necessary. Ultimately, the world must decide whether the global good of polio eradication is worth achieving. For us in the programme, we would like to stay with a disease 'that future generations know by history only…' 23 and not one that future generations will blame us for giving up so close to the finishing line and failing to wipe out once and for all.
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